Does 3D Bioprinting Work? Insights & Applications

At first glance, 3D bioprinting might seem like a concept straight out of a science fiction novel. The notion that we can now print living tissues, organs, and constructs using bio-inks and printers is a groundbreaking leap in medical science and technology. This innovative process transcends traditional boundaries, offering not just a new way to create and test drugs but also holding the promise of revolutionizing organ transplantation. 

The precision of 3D printing, combined with the complexities of biological materials, brings us closer to solving some of the most persistent challenges in the field of medicine. “When you see it, you definitely have a feeling that you’re in the future,” says Kevin Coker, founder and chief executive officer at Proxima Clinical Research. “I’ve been fortunate to be around it for the last five years now, and I’m just absolutely amazed at what researchers and companies have been able to achieve. Now, we even have hospitals that have their own custom bioprinting shops for surgery.”

And it works exactly like it sounds. 3D bioprinting uses additive manufacturing techniques to fabricate tissue and organ constructs using biomaterials. This technology harnesses the precision of 3D printing to layer living cells, referred to as bioinks, to create structures that can mimic natural tissues in both functionality and structure. Its vast and varied applications range from tissue engineering and regenerative medicine to drug testing and developmental biology.

This interdisciplinary field blends expertise from biology, material science, engineering, and computer science to refine and enhance bioprinting technologies. As research continues, the focus is not only on improving the resolution and fidelity of printed tissues but also on developing bioinks that can more accurately mimic the cellular environment, thereby promoting cell survival and integration post-printing.

In early 2026, the Advanced Research Projects Agency for Health (ARPA-H) awarded a team at UC San Diego, led by nanoengineering professor Shaochen Chen, up to $25.8 million to 3D bioprint a patient-specific human liver. Chen, a pioneer of light-based bioprinting, spoke with us about how far the technology has come and how close it really is to producing an organ a surgeon could implant.

Printing a full, functional organ, long considered the field’s ultimate goal, is now the explicit target of well-funded research. In early 2026, the Advanced Research Projects Agency for Health (ARPA-H) awarded a team at UC San Diego up to $25.8 million to 3D bioprint a patient-specific human liver. Leading that project is Shaochen Chen, a nanoengineering professor and longtime pioneer of light-based bioprinting: “It’s doable,” he says. “It just needs a lot of money and time to do it.”

Keep reading to learn more about bioprinting, current applications, ethical concerns, and what the future might hold for this pioneering field.

Why Light Changed the Game

Most bioprinting relies on an extruder that pushes material through a nozzle, layer by layer. Dr. Chen’s lab instead uses light, a decision that has proven critical for printing with living cells.

“Printing a sizeable piece, like a computer mouse, would take about eight hours using a traditional extrusion printer,” Dr. Chen explains. “Using our light-based printer, it takes only a couple of minutes. That is significant, because we are printing living cells. Outside the incubator, the cells don’t survive for more than two hours, so this speed is essential.” The approach earned a nickname in the field: lightning-speed printing.

Resolution is the second advantage. Because cells are only a few microns across, resolution determines how faithfully a printed tissue reproduces real biology. “With extrusion, you use a nozzle to squeeze the material out, and you’re limited by the size of the tip, typically a couple hundred microns,” Dr. Chen says. “Cells are on the order of a couple microns, so the features are very rough. With light, we don’t have that physical constraint. We just shine the light, the gel polymerizes, the cells are embedded inside, and you let them grow.” Extrusion can also damage the cell membrane as cells are forced through the nozzle. Over the years, Dr. Chen’s group has used the technique to print heart, liver, and brain tumor tissue, as well as muscle and spinal cord constructs.

The Organ Question: What’s Real, and When

Ask the public about printed organs, and they imagine a finished liver lifted out of a machine, ready to transplant. Dr. Chen is candid that the reality is more staged than that, and that the near-term payoff looks different from the headline.

In practice, that means small, printed tissues for drug testing rather than whole organs for transplant. Because they are small, these micro-tissues don’t require a blood supply, which makes them far easier to produce. “Those are the low-hanging fruit,” Dr. Chen says. “You don’t worry about vascularization, and they are very powerful for drug testing. Both NIH and FDA are promoting these so-called NAMs, or new approach methodologies.” As regulators steer away from animal testing toward these human-tissue models, Dr. Chen expects pharmaceutical companies to adopt them more quickly. Full organ repair and replacement, by contrast, is “the long shot.”

But that long shot now has a concrete roadmap. Dr. Chen’s ARPA-H project aims to print a functioning liver, and he lays out the timeline plainly: “We have a goal to demonstrate printing within the first three years in a rat model,” he says, referring to a liver on the order of a centimeter. “If it’s successful, within the next two years we will translate to a humanized pig,” roughly human scale. Only then would clinical trials follow. His overall estimate for a human-ready organ is five to ten years.

Dr. Chen’s liver project is not the only organ-printing effort in this cohort. It is one of several awards under ARPA-H’s organ-bioprinting push, alongside a Stanford team led by Mark Skylar-Scott working under a $26.3 million contract to bioprint a human heart and implant it in a pig within five years, and a Wake Forest Institute for Regenerative Medicine effort led by Anthony Atala with an award of up to $24.8 million to produce on-demand, vascularized kidney tissue.

Asked directly whether we’ll ever see an implantable printed heart, kidney, or liver, Dr. Chen is direct: “It’s doable. It just needs a lot of money and time to do it.” That work, he stresses, will have to come from industry rather than universities. “It has to come from a company. I don’t know how a university can make money taking an organ to market,” he says. 

Vascularization: The Problem That Has to Be Solved

For years, vascularization, or giving printed tissue a blood supply, has been bioprinting’s signature unsolved problem. Small tissues don’t need it, because nutrients reach the cells from the surrounding culture media. Anything organ-sized does.

“If you talk to any surgeon and say you can print a liver, the first thing he’ll ask is, ‘Where do I hook up with the vasculature of the body?’” Dr. Chen says. “If you cannot connect to the body’s own vascular system, the organ will die immediately. It’s a total waste of time and money.” The engineering constraint is unforgiving: cells can only survive within roughly two to three hundred microns of a blood vessel, so a working organ needs a dense, embedded network of fine channels threaded through the printed cells. 

Dr. Chen sees this as the key advantage of light-based printing. “Our light-based printing technology is truly superior to any other technology for making this embedded microvascular network within the printed tissue,” he says. According to Dr. Chen, his lab can already build these networks into printed tissue.

Better Biomaterials, and AI to Guide Them

The bioinks themselves have advanced steadily. “Usually we start with synthetic materials, then we figure out that natural materials are better, like gelatin or collagen,” Dr. Chen says. “But when you go to human clinical uses, you have to use human-based biomaterials.” Several companies are now commercializing exactly that, using material from donors.

Artificial intelligence has become an essential part of the workflow. Its first job is dialing in the print itself. “When we do printing, you actually don’t know the optimal parameters: how much light, how long to expose, what concentration of materials,” Dr. Chen explains. “AI is very useful to guide you,” he shares.

Its second, more consequential job is designing the vasculature. “We want to make sure the network can cover the entire volume of the tissue we’re printing. It’s very difficult to do by hand,” he says. “It’s better to do it with AI. We train the AI, and it tells us the layout.”

What It Will Take

The biggest obstacle now, Dr. Chen says, is not the technology but money and manufacturing scale. “This is a very promising field, but it’s expensive work,” he says. “When you try to build an organ, you need industrial-scale manufacturing. All these cells are expensive. You need standards for production. The society really has to support the work.” It’s an echo of a point Coker made in 2024 that the remaining barrier is increasingly financial rather than purely technical.

For Dr. Chen, the motivation is ultimately about aging populations and quality of life, not novelty. “It’s important not just to live longer, but to live healthier and happier,” he says. “You need support like this to repair some of the damaged parts and make it better. The societal impact is huge.”

Current State of Bioprinting

Despite its recent arrival in medicine, bioprinting has already made significant strides. Current applications include creating personalized skin grafts for burn victims, developing models for drug testing and disease research, and producing tissues for transplantation. Bioprinting has the potential to revolutionize the way we approach medical treatments by providing a more precise and effective means of repairing or replacing damaged tissue.

One of the early applications of 3D bioprinting was cartilage: “They started with creating cartilaginous bioprinting materials. One of the first things to print was an ear, which could be used as a replacement for people who have had injuries,” explains Coker. Now, we’re talking about printing much more complex and complicated structures. Hospitals are creating their own labs to have these custom-made organ-like products available for surgeons. It is absolutely mind-blowing.”

However, there are many challenges researchers have had to tackle. “We have resolved several challenges with the technology. One of those is printing with enough resolution to get cellular structures. Before, it was very difficult to print at such a small level,” says Coker. “It’s almost like a pixel on your TV. Now, we can print at a microscopic level of resolution to essentially allow single-cell printing to occur. We have also solved several other hurdles with regard to printing different cell types and print structures for vascularization or innervation of nerves. The industry has moved forward significantly in the last five years.”

He continues, “A number of companies have developed the ability to print at depth, so not only are you printing at a small enough resolution where you can print at the cellular level, but you can now print layer on top of layer to have a significant amount of tissue build up to develop organoid structures and hopefully, ultimately, organs. That’s ultimately what everyone is hoping for the next few years.”

How 3-D Bioprinting Works

The bioprinting process begins with creating a 3D model of the desired tissue or organ using imaging techniques such as MRI or CT scans. This digital model is then sent to the printer, which uses bioinks containing living cells and other biomaterials to print layer by layer, following the computer-generated design. The 3D printers are very similar to traditional ones, but instead of using a filament, they are designed to use a liquid or a gel. “It is a proprietary bioink that flows through the printer. It comes out almost like water from a hose,” explains Coker. “The bioink contains a polymer that reacts with other agents, whether that be air or light, and then turns into a solid or semi-solid state.”

The bioink is truly what makes the whole process work. “They mix the ink along with cellular tissue. The challenge has been to make cells get through the nozzle and then polymerize,” he says. “One of the clever things that Volumetric Biotechnologies did was use light to polymerize the material utilizing food coloring. It was groundbreaking and disruptive for them at the time.”

Applications for 3D Bioprinting

Bioengineering, particularly 3D bioprinting, is advancing at an unprecedented pace, driven by continuous technological innovations and interdisciplinary collaborations. This rapid progression is delineated by the exponential growth in research output, patent filings, and clinical applications that have emerged over the last decade. Advances in biomaterials, design software, and printing technologies have collectively enabled the creation of more complex, functional, and personalized tissues and organs. “It has been hard to keep up, to be honest,” admits Coker. “A great resource for learning about the newest advancement is Jenny Chen’s website, 3DHEALS. She keeps track of all the things we can now print. I even saw an article by her recently about printing hair follicles.”  

Currently, the list of things that can be 3D bioprinted includes:

• Skin tissues for grafts and regenerative medicine
• Cartilage for joint repair and replacement
• Bones, including complex structures for cranial and facial reconstruction
• Blood vessels and microvascular networks
• Heart valves and cardiac tissue for repair and testing
• Liver tissue for disease modeling and drug screening
• Kidney and pancreas tissues for understanding and treating organ diseases
• Corneas for eye repair and research
• Nerve tissue for repairing damaged nerves and spinal cord injuries

Ethical Considerations in 3D Bioprinting

As with any new technology, 3D bioprinting raises ethical concerns regarding its use and potential impact on society. A primary concern is the affordability and accessibility of 3D bioprinting technology. Currently, it remains an expensive and complex process, making it inaccessible for many people who may benefit from it. As the technology advances and becomes more widespread, it will be essential to ensure that it is accessible to everyone who could benefit from it. 

There are also concerns about the long-term effects of using 3D bioprinted tissues and organs in humans. Extensive research and testing will need to be done to ensure their safety and efficacy before they can be used in clinical settings. “To what extent can we develop an organ and implant it in a person? How can you know that someone is ready for that? If you are a patient who needs a new liver or heart, and you have been on the transplant list for a while, you may say that you are ready for it today because it is your last hope. That’s a huge responsibility to ensure the technology is ready and beneficial,” explains Coker. “Like AI, we don’t know where this technology will go, and we need to be cautious.” 

Future of 3D Bioprinting

The potential for 3D bioprinting to revolutionize the healthcare industry is immense. As the technology continues to advance, it has the potential to significantly improve patient outcomes and quality of life by providing personalized and functional tissue and organ replacements. “We are in a very exciting time. The hardware technology and the ability to print organ-like structures is very close,” says Coker. “However, I think the gap that exists today is a monetary one. It will take investors and investment to help us bridge from where we are today into what will be a marketed product.” 

He continues, “ Right now, we’ve got the ability to print organelles, small organoid structures, and cartilaginous material. We need more investors to take a bit more risk, invest in more companies and more technologies, and help to bring this all together. Five years ago, it was a technological problem, but today we just need the financing to bring printed organs to the market.”